Arvinas Operations Inc. has disclosed proteolysis targeting chimera (PROTACs) compounds comprising a cereblon (CRBN) E3 ubiquitin ligase-binding moiety covalently linked to a B-cell lymphoma 6 protein (BCL-6)-targeting moiety through a linker with potential for use in the treatment of cancer.
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has prepared and tested molecular glue degraders comprising E3 ubiquitin-protein ligases acting as proto-oncogene Vav (VAV1) degradation inducers reported to be useful for the treatment of inflammation and autoimmune diseases.
Daiichi Sankyo Co. Ltd. has disclosed new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to a steroidogenic factor 1 (SF-1)-targeting moiety. They are reported to be potentially useful for the treatment of primary aldosteronism, Cushing syndrome and cancer.
A new Danish research project focused on Parkinson’s disease has received funding from Innovation Fund Denmark. The DESYNA (Degradation of Extracellular α-SYNuclein Aggregates) project aims to develop a new therapy targeting α-synuclein, the accumulation of which is a key driver of Parkinson’s disease.
Treeline Biosciences Inc. has synthesized new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to transcriptional enhancer factor TEF (TEAD)-targeting moiety potentially useful for the treatment of cancer.
Beijing Innocare Pharma Tech Co. Ltd. and Innocare Pharma Inc. have patented molecular glue degraders acting as VAV1 degradation inducers. They are reported to be useful for the treatment of autoimmune disease and inflammatory disorders.
A University of Texas System patent describes new YAP1 degradation inducing proteolysis targeting chimeras (PROTACs) designed for use in the treatment of cancer.
Humanwell Healthcare (Group) Co. Ltd. has divulged molecular glue degraders comprising cereblon (CRBN)-binding agents acting as proto-oncogene Vav (VAV1) degradation inducers. They are reported to be useful for the treatment of autoimmune disease, cancer, inflammatory bowel disease, multiple sclerosis, myasthenia gravis, periodontitis, psoriasis, rheumatoid arthritis and type I diabetes, among others.
A patent from Gilead Sciences Inc. has divulged GTPase KRAS (G12D mutant) inhibitors and proteolysis targeting chimeras (PROTACS) comprising an E3 ubiquitin ligase-binding moiety covalently linked to a GTPase KRAS (G12D mutant)-targeting moiety through linker.
A Risen (Shanghai) Pharma Eng Co. Ltd. and Risen (Suzhou) Pharma Tech Co. Ltd. patent describes the discovery of new proteolysis targeting chimera (PROTAC) compounds comprising a E3 ubiquitin ligase-binding moiety covalently linked to a GTPase KRAS-targeting moiety. They are reported to be useful for the treatment of cancer.
RSS
